387 related articles for article (PubMed ID: 28918995)
1. Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.
Ransohoff JD; Kwong BY
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):834-851. PubMed ID: 28918995
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous Complications of Targeted Melanoma Therapy.
de Golian E; Kwong BY; Swetter SM; Pugliese SB
Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
4. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
6. The immunoproteasome as a therapeutic target for hematological malignancies.
Miller Z; Lee W; Kim KB
Curr Cancer Drug Targets; 2014; 14(6):537-48. PubMed ID: 25059201
[TBL] [Abstract][Full Text] [Related]
7. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.
Gnanendran SS; Turner LM; Miller JA; Hwang SJE; Miller AC
Curr Treat Options Oncol; 2020 Mar; 21(4):29. PubMed ID: 32193712
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
10. [Molecular targeted therapy in lymphoid leukemias].
Kojima K; Ando T; Kimura S
Nihon Rinsho; 2014 Jun; 72(6):1094-8. PubMed ID: 25016810
[TBL] [Abstract][Full Text] [Related]
11. Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer.
Tang N; Ratner D
Dermatol Surg; 2016 Jan; 42 Suppl 1():S40-8. PubMed ID: 26730973
[TBL] [Abstract][Full Text] [Related]
12. Targeted agents: management of dermatologic toxicities.
Burtness B
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):793-6. PubMed ID: 24853219
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.
Marchetti M
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):469-480. PubMed ID: 28796569
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of nontargeted and targeted chemotherapies.
Shi VJ; Levy LL; Choi JN
Semin Oncol; 2016 Jun; 43(3):419-25. PubMed ID: 27178698
[TBL] [Abstract][Full Text] [Related]
17. [Management of adverse effects of targeted therapy toxicities in oncology].
Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
[TBL] [Abstract][Full Text] [Related]
18. Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies.
Tragiannidis A; Groll AH
Paediatr Drugs; 2021 Sep; 23(5):445-455. PubMed ID: 34292515
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]